Company / Operating Cash Flow
Myriad Genetics, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$1.8M
FY2025
5-year range
-$110.9M / $18.6M
FY2021-FY2025
Trend
+120.7%
vs FY2024
Sector context
#75 of 216
Health Care
What the data says
At $2M, Myriad Genetics, Inc.'s operating cash flow ranks #75 of 216 in the Health Care sector. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$111M in FY2023 to $166M in FY2016.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -50.5%.
Improved from -$111M to $2M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -50.5%
- 10-Year CAGR
- -
Sector benchmark
#75 of 216 in Health CareTop 35% of 216This company $1.8M Sector average $659.0M
▼
-99.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -50.5%, indicating a declining trend.
- In FY2025, operating cash flow increased 120.7% year-over-year.
- Ranks #75 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.8M | +120.7% |
| FY2024 | -$8.7M | +92.2% |
| FY2023 | -$110.9M | -4.3% |
| FY2022 | -$106.3M | -671.5% |
| FY2021 | $18.6M | -69.4% |
| FY2020 | $60.7M | -42.8% |
| FY2019 | $106.2M | -8.4% |
| FY2018 | $115.9M | +9.1% |
| FY2017 | $106.2M | -36.1% |
| FY2016 | $166.3M | +18.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026